BACKGROUND. Cachectin, or tumor necrosis factor-alpha (TNF-alpha), is a principal mediator of the inflammatory response and may be important in the pathogenesis and progression of multiple sclerosis, an inflammatory disease of the central nervous system. METHODS. In a 24-month prospective study, we used a sensitive enzyme-linked immunosorbent assay to determine levels of TNF-alpha in cerebrospinal fluid and serum in 32 patients with chronic progressive multiple sclerosis and in 20 with stable multiple sclerosis and 85 with other neurologic diseases. An attempt was made to relate TNF-alpha levels with the degree of disability of the patients with multiple sclerosis and with their neurologic deterioration during the 24 months of observation. RESULTS. High levels of TNF-alpha were found in the cerebrospinal fluid of 53 percent of the patients with chronic progressive multiple sclerosis and in none of those with stable multiple sclerosis (P less than 0.001). TNF-alpha was detected in the cerebrospinal fluid of 7 percent of the controls (P less than 0.01) with other neurologic disease. In patients with chronic progressive multiple sclerosis, mean TNF-alpha levels were significantly higher in the cerebrospinal fluid than in corresponding serum samples (52.41 vs. 11.88 U per milliliter; range, 2 to 178 vs. 2 to 39; P less than 0.001). In these patients, cerebrospinal fluid levels of TNF-alpha correlated with the degree of disability (r = 0.834, P less than 0.001) and the rate of neurologic deterioration (r = 0.741, P less than 0.001) before the start of the study. Cerebrospinal fluid levels also correlated with the increase in neurologic disability after 24 months of observation (r = 0.873, P less than 0.001). CONCLUSIONS. These data provide evidence of intrathecal synthesis of TNF-alpha in multiple sclerosis and suggest that the level of TNF-alpha in cerebrospinal fluid correlates with the severity and progression of the disease. Our results suggest that TNF-alpha may reflect histologic disease activity in multiple sclerosis and could be used to monitor outcomes or responses to therapy.
Source Information
Department of Clinical Neurochemistry, National Hospital for Neurology and Neurosurgery, London, United Kingdom.
This article has been cited by other articles:
Weinger, J. G., Omari, K. M., Marsden, K., Raine, C. S., Shafit-Zagardo, B.
(2009). Up-Regulation of Soluble Axl and Mer Receptor Tyrosine Kinases Negatively Correlates with Gas6 in Established Multiple Sclerosis Lesions. Am. J. Pathol.
175: 283-293
[Abstract][Full Text]
Kumpfel, T., Hoffmann, L-A, Pellkofer, H., Pollmann, W., Feneberg, W., Hohlfeld, R., Lohse, P.
(2008). Multiple sclerosis and the TNFRSF1A R92Q mutation: Clinical characteristics of 21 cases. Neurology
71: 1812-1820
[Abstract][Full Text]
Zehntner, S. P., Bourbonniere, L., Moore, C. S., Morris, S. J., Methot, D., St. Jean, M., Lacasse, E., Hebb, A. L. O., Robertson, G. S., Durkin, J., Gillard, J. W., Owens, T.
(2007). X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function. J. Immunol.
179: 7553-7560
[Abstract][Full Text]
Gaffo, A., Saag, K. G., Curtis, J. R.
(2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm
63: 2451-2465
[Abstract][Full Text]
Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L.
(2006). The value of animal models for drug development in multiple sclerosis. Brain
129: 1940-1952
[Abstract][Full Text]
Dasgupta, S., Jana, M., Liu, X., Pahan, K.
(2005). Myelin Basic Protein-primed T Cells of Female but Not Male Mice Induce Nitric-oxide Synthase and Proinflammatory Cytokines in Microglia: IMPLICATIONS FOR GENDER BIAS IN MULTIPLE SCLEROSIS. J. Biol. Chem.
280: 32609-32617
[Abstract][Full Text]
Frohman, E. M., Filippi, M., Stuve, O., Waxman, S. G., Corboy, J., Phillips, J. T., Lucchinetti, C., Wilken, J., Karandikar, N., Hemmer, B., Monson, N., De Keyser, J., Hartung, H., Steinman, L., Oksenberg, J. R., Cree, B. A. C., Hauser, S., Racke, M. K.
(2005). Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions. Arch Neurol
62: 1345-1356
[Abstract][Full Text]
Soilu-Hanninen, M., Koskinen, J. O., Laaksonen, M., Hanninen, A., Lilius, E. -M., Waris, M.
(2005). High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology
65: 153-155
[Abstract][Full Text]
Ishizu, T., Osoegawa, M., Mei, F.-J., Kikuchi, H., Tanaka, M., Takakura, Y., Minohara, M., Murai, H., Mihara, F., Taniwaki, T., Kira, J.-i.
(2005). Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain
128: 988-1002
[Abstract][Full Text]
Walker, J. E, Giri, S. N, Margolin, S. B
(2005). A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler
11: 149-158
[Abstract]
Horneff, G, Schmeling, H, Biedermann, T, Foeldvari, I, Ganser, G, Girschick, H J, Hospach, T, Huppertz, H I, Keitzer, R, Kuster, R M, Michels, H, Moebius, D, Rogalski, B, Thon, A, for the Paediatric Rheumatology Collaborative Grou,
(2004). The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis
63: 1638-1644
[Abstract][Full Text]
Murphy, C C, Duncan, L, Forrester, J V, Dick, A D
(2004). Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol
88: 412-416
[Abstract][Full Text]
Oleszak, E. L., Chang, J. R., Friedman, H., Katsetos, C. D., Platsoucas, C. D.
(2004). Theiler's Virus Infection: a Model for Multiple Sclerosis. Clin. Microbiol. Rev.
17: 174-207
[Abstract][Full Text]
Bomprezzi, R., Ringner, M., Kim, S., Bittner, M. L., Khan, J., Chen, Y., Elkahloun, A., Yu, A., Bielekova, B., Meltzer, P. S., Martin, R., McFarland, H. F., Trent, J. M.
(2003). Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet
12: 2191-2199
[Abstract][Full Text]
Dasgupta, S., Jana, M., Liu, X., Pahan, K.
(2003). Role of Very-late Antigen-4 (VLA-4) in Myelin Basic Protein-primed T Cell Contact-induced Expression of Proinflammatory Cytokines in Microglial Cells. J. Biol. Chem.
278: 22424-22431
[Abstract][Full Text]
Sturzebecher, S., Wandinger, K. P., Rosenwald, A., Sathyamoorthy, M., Tzou, A., Mattar, P., Frank, J. A., Staudt, L., Martin, R., McFarland, H. F.
(2003). Expression profiling identifies responder and non-responder phenotypes to interferon-{beta} in multiple sclerosis. Brain
126: 1419-1429
[Abstract][Full Text]
Seifert, T, Kieseier, B C, Ropele, S, Strasser-Fuchs, S, Quehenberger, F, Fazekas, F, Hartung, H-P
(2002). TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis. Mult Scler
8: 447-451
[Abstract]
Rosenberg, G. A.
(2002). Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis. Neuroscientist
8: 586-595
[Abstract]
Ozenci, V, Kouwenhoven, M, Link, H
(2002). Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler
8: 396-404
[Abstract]
Erkut, Z A, Endert, E, Huitinga, I, Swaab, D F
(2002). Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis. Mult Scler
8: 229-236
[Abstract]
May, L-A, Huang, Q, Morris, D, Danis, V, Manolios, N
(2002). Relationship of tumour necrosis factor alpha gene polymorphisms and neuropsychiatric lupus. Lupus
11: 114-118
[Abstract]
Goncalves, N. S., Ghaem-Maghami, M., Monteleone, G., Frankel, G., Dougan, G., Lewis, D. J. M., Simmons, C. P., MacDonald, T. T.
(2001). Critical Role for Tumor Necrosis Factor Alpha in Controlling the Number of Lumenal Pathogenic Bacteria and Immunopathology in Infectious Colitis. Infect. Immun.
69: 6651-6659
[Abstract][Full Text]
Sorensen, T. L., Sellebjerg, F.
(2001). Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology
57: 1371-1376
[Abstract][Full Text]
Killestein, J., Kalkers, N. F., Meilof, J. F., Barkhof, F., van Lier, R. A. W., Polman, C. H.
(2001). TNF{alpha} production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS. Neurology
57: 1129-1131
[Abstract][Full Text]
Collins, R. A., Grounds, M. D.
(2001). The Role of Tumor Necrosis Factor-alpha (TNF-{alpha}) in Skeletal Muscle Regeneration: Studies in TNF-{alpha}(-/-) and TNF-{alpha}(-/-)/LT-{alpha}(-/-) Mice. J. Histochem. Cytochem.
49: 989-1002
[Abstract][Full Text]
Mark, K. S., Trickler, W. J., Miller, D. W.
(2001). Tumor Necrosis Factor-alpha Induces Cyclooxygenase-2 Expression and Prostaglandin Release in Brain Microvessel Endothelial Cells. J. Pharmacol. Exp. Ther.
297: 1051-1058
[Abstract][Full Text]
Kadhim, H., Tabarki, B., Verellen, G., De Prez, C., Rona, A.-M., Sebire, G.
(2001). Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology
56: 1278-1284
[Abstract][Full Text]
Minagar, A., Jy, W., Jimenez, J. J., Sheremata, W. A., Mauro, L. M., Mao, W. W., Horstman, L. L., Ahn, Y. S.
(2001). Elevated plasma endothelial microparticles in multiple sclerosis. Neurology
56: 1319-1324
[Abstract][Full Text]
Kassiotis, G., Kollias, G.
(2001). Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level: Implications for Pathogenesis and Therapy of Autoimmune Demyelination. JEM
193: 427-434
[Abstract][Full Text]
Mayne, M., Ni, W., Yan, H. J., Xue, M., Johnston, J. B., Del Bigio, M. R., Peeling, J., Power, C., Feuerstein, G. Z., Ho, S., Wang, X.
(2001). Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor-{{alpha}} Expression Is Neuroprotective After Intracerebral Hemorrhage Editorial Comment. Stroke
32: 240-248
[Abstract][Full Text]
Tejada-Simon, M. V., Zang, Y. C. Q., Yang, D., Hong, J., Li, S., Singh, R. A. K., Van den Berg-Loonen, E., Killian, J. M., Rivera, V. M., Zhang, J. Z.
(2000). Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol
12: 1641-1650
[Abstract][Full Text]
Chabot, S., Yong, V. W.
(2000). Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: Relevance to MS. Neurology
55: 1497-1505
[Abstract][Full Text]
Selmaj, K. W
(2000). Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis
59: i94-102
[Full Text]
da Costa, P. M., Yasuda, C. L., Scagliusi, S. M, Diaz-Bardales, B. M., Maciel, E., Damasceno, B. P, Blotta, M H. S., Tilbery, C. P, Santos, L. M.
(2000). pattern of cytokine secretion by peripheral blood cells of patients with multiple sclerosis in Brazil. Mult Scler
6: 293-299
[Abstract]
Probert, L., Eugster, H.-P., Akassoglou, K., Bauer, J., Frei, K., Lassmann, H., Fontana, A.
(2000). TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain
123: 2005-2019
[Abstract][Full Text]
Zang, Y. C. Q., Samanta, A. K., Halder, J. B., Hong, J., Tejada-Simon, M. V., Rivera, V. M., Zhang, J. Z.
(2000). Aberrant T cell migration toward RANTES and MIP-1{alpha} in patients with multiple sclerosis: Overexpression of chemokine receptor CCR5. Brain
123: 1874-1882
[Abstract][Full Text]
Zang, Y. C. Q., Yang, D., Hong, J., Tejada-Simon, M. V., Rivera, V. M., Zhang, J. Z.
(2000). Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology
55: 397-404
[Abstract][Full Text]
Khoury, S. J., Guttmann, C. R. G., Orav, E. J., Kikinis, R., Jolesz, F. A., Weiner, H. L.
(2000). Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis. Arch Neurol
57: 1183-1189
[Abstract][Full Text]
Kallmann, B. A., Hummel, V., Lindenlaub, T., Ruprecht, K., Toyka, K. V., Rieckmann, P.
(2000). Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain
123: 687-697
[Abstract][Full Text]
Petereit, H F, Richter, N, Pukrop, R, Bamborschke, S
(2000). Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler
6: 19-23
[Abstract]
Kozovska, M. E., Hong, J., Zang, Y. C. Q., Li, S., Rivera, V. M., Killian, J. M., Zhang, J. Z.
(1999). Interferon beta induces T-helper 2 immune deviation in MS. Neurology
53: 1692-1692
[Abstract][Full Text]
Jurewicz, A. M., Walczak, A. K., Selmaj, K. W.
(1999). Shedding of TNF receptors in multiple sclerosis patients. Neurology
53: 1409-1409
[Abstract][Full Text]
Huang, W.-X., Huang, P., Link, H., Hillert, J.
(1999). Cytokine analysis in multiple sclerosis by competitive RT - PCR: A decreased expression of IL-10 and an increased expression of TNF-{alpha} in chronic progression. Mult Scler
5: 342-348
[Abstract]
Smith, M. E., Eller, N. L., McFarland, H. F., Racke, M. K., Raine, C. S.
(1999). Age Dependence of Clinical and Pathological Manifestations of Autoimmune Demyelination : Implications for Multiple Sclerosis. Am. J. Pathol.
155: 1147-1161
[Abstract][Full Text]
Khoury, S. J., Orav, E. J., Guttmann, C. R. G., Kikinis, R., Jolesz, F. A., Weiner, H. L.
(1999). Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology
53: 758-758
[Abstract][Full Text]
Azzawi, M., Hasleton, P.
(1999). Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease. Cardiovasc Res
43: 850-859
[Full Text]
Arnason,
(1999). TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology
53: 457-457
[Abstract][Full Text]
Gayo, A., Mozo, L., Suarez, A., Tunon, A., Lahoz, C., Gutierrez, C.
(1999). Interferon beta-1b treatment modulates TNF{alpha} and IFN{gamma} spontaneous gene expression in MS. Neurology
52: 1764-1764
[Abstract][Full Text]
Myhr, K.-M., Raknes, G., Nyland, H., Vedeler, C.
(1999). Immunoglobulin G Fc-receptor (Fc{gamma}R) IIA and IIIB polymorphisms related to disability in MS. Neurology
52: 1771-1771
[Abstract][Full Text]
Sharief, M. K., Ingram, D. A., Swash, M., Thompson, E. J.
(1999). IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology
52: 1833-1833
[Abstract][Full Text]
Yoshikawa, M., Suzumura, A., Tamaru, T., Takayanagi, T., Sawada, M.
(1999). Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler
5: 126-133
[Abstract]
Goodkin, D. E.
(1998). Serial Magnetization Transfer Ratio Imaging Of MS. Mult Scler
4: 503-505
Akassoglou, K., Bauer, J., Kassiotis, G., Pasparakis, M., Lassmann, H., Kollias, G., Probert, L.
(1998). Oligodendrocyte Apoptosis and Primary Demyelination Induced by Local TNF/p55TNF Receptor Signaling in the Central Nervous System of Transgenic Mice : Models for Multiple Sclerosis with Primary Oligodendrogliopathy. Am. J. Pathol.
153: 801-813
[Abstract][Full Text]
Kubota, R., Kawanishi, T., Matsubara, H., Manns, A., Jacobson, S.
(1998). Demonstration of Human T Lymphotropic Virus Type I (HTLV-I) Tax-Specific CD8+ Lymphocytes Directly in Peripheral Blood of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients by Intracellular Cytokine Detection. J. Immunol.
161: 482-488
[Abstract][Full Text]
Giovannoni, G, Green, A J., Thompson, E J
(1998). Are there any body fluid markers of brain atrophy in multiple sclerosis?. Mult Scler
4: 138-142
[Abstract]
Monteyne, P., Sindic, C. J.
(1998). Data on cytokine mRNA expression in CSF and peripheral blood mononuclear cells from MS patients as detected by PCR. Mult Scler
4: 143-146
[Abstract]
Reder, A. T, Genc, K., Byskosh, P. V, Porrini, A. M.
(1998). Monocyte activation in multiple sclerosis. Mult Scler
4: 162-168
[Abstract]
Sharief, M K
(1998). Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination?. Mult Scler
4: 169-173
[Abstract]
van Oosten, B. W., Barkhof, F., Scholten, P. E. T., von Blomberg, B. M. E., Ader, H. J., Polman, C. H.
(1998). Increased Production of Tumor Necrosis Factor {alpha}, and Not of Interferon {gamma}, Preceding Disease Activity in Patients With Multiple Sclerosis. Arch Neurol
55: 793-798
[Abstract][Full Text]
Martiney, J. A., Rajan, A. J., Charles, P. C., Cerami, A., Ulrich, P. C., Macphail, S., Tracey, K. J., Brosnan, C. F.
(1998). Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by CNI-1493, a Macrophage-Deactivating Agent. J. Immunol.
160: 5588-5595
[Abstract][Full Text]
Link, H.
(1998). The cytokine storm in multiple sclerosis. Mult Scler
4: 12-15
[Abstract]
Whitaker, J. N
(1998). Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler
4: 16-21
[Abstract]
Vora, A., Kidd, D., Miller, D., Perkin, G., Hughes, R., Ellis, B., Dumonde, D., Brown, K.
(1997). Lymphocyte-endothelial cell interactions in multiple sclerosis: disease specificity and relationship to circulating tumour necrosis factor-{alpha} and soluble adhesion molecules. Mult Scler
3: 171-179
[Abstract]
Shen, Y., Li, R., Shiosaki, K.
(1997). Inhibition of p75 Tumor Necrosis Factor Receptor by Antisense Oligonucleotides Increases Hypoxic Injury and beta -Amyloid Toxicity in Human Neuronal Cell Line. J. Biol. Chem.
272: 3550-3553
[Abstract][Full Text]
Abramsky, O, Lehmann, D, Karussis, D
(1996). Immunomodulation with linomide: possible novel therapy for multiple sclerosis. Mult Scler
2: 206-210
[Abstract]
Friedman, J. E., Zabriskie, J., Bourganskaia, E.
(1996). A Pilot Study of Pentoxifylline in Multiple Sclerosis. Arch Neurol
53: 956-957
[Abstract]
Hohlfeld, R.
(1996). Inhibitors of tumor necrosis factor-{alpha}: Promising agents for the treatment of multiple sclerosis?. Mult Scler
1: 376-378
[Abstract]
Goodkin, D. E
(1996). MS clinical trial design for the future. Mult Scler
1: 393-399
[Abstract]
Byskosh, P., Reder, A.
(1996). Interferon {beta}-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler
1: 262-269
[Abstract]
Rudick, R., Medendorp, S., Namey, M, Boyle, S, Fischer, J
(1995). Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains. Mult Scler
1: 150-155
[Abstract]
Sandberg-Wollheim, M, Ciusani, E, Salmaggi, A, Pociot, F
(1995). An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis. Mult Scler
1: 181-185
[Abstract]
Whitaker, J., McFarland, H., Rudge, P, Reingold, S.
(1995). Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler
1: 37-47
[Abstract]
Watanabe, H., Nakamura, T., Nagasato, K., Shirabe, S., Ohishi, K., Ichinose, K., Nishiura, Y., Chiyoda, S., Tsujihata, M., Nagataki, S.
(1995). Exaggerated Messenger RNA Expression of Inflammatory Cytokines in Human T-Cell Lymphotropic Virus Type I--Associated Myelopathy. Arch Neurol
52: 276-280
[Abstract]
Oksenberg, J. R., Begovich, A. B., Erlich, H. A., Steinman, L.
(1993). Genetic Factors in Multiple Sclerosis. JAMA
270: 2362-2369
[Abstract]
Hollsberg, P., Hafler, D. A.
(1993). Pathogenesis of Diseases Induced by Human Lymphotropic Virus Type I Infection. NEJM
328: 1173-1182
[Full Text]
Louis, J., Magal, E, Takayama, S, Varon, S
(1993). CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science
259: 689-692
[Abstract]
Joynt, R. J.
(1992). Neurology. JAMA
268: 380-382
[Abstract]
Soilu-Hanninen, M., Koskinen, J. O., Laaksonen, M., Hanninen, A., Lilius, E. -M., Waris, M.
(2005). High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology
65: 153-155
[Abstract][Full Text]
Previous
